{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:28:53Z","timestamp":1759616933175},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,5,24]],"date-time":"2008-05-24T00:00:00Z","timestamp":1211587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1471-2334-8-71","type":"journal-article","created":{"date-parts":[[2008,5,24]],"date-time":"2008-05-24T18:13:00Z","timestamp":1211652780000},"source":"Crossref","is-referenced-by-count":9,"title":["Fluoroquinolone resistance during 2000\u20132005 : An observational study"],"prefix":"10.1186","volume":"8","author":[{"given":"Richard J","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Lindsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,24]]},"reference":[{"key":"662_CR1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.addr.2005.04.005","volume":"57","author":"GL French","year":"2005","unstructured":"French GL: Clinical impact and relevance of antibiotic resistance. Advanced Drug Delivery Reviews. 2005, 57: 1514-1527. 10.1016\/j.addr.2005.04.005.","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"5","key":"662_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/cc3757","volume":"9","author":"MH Kollef","year":"2005","unstructured":"Kollef MH: Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Crit Care. 2005, 9 (5): 459-64. 10.1186\/cc3757.","journal-title":"Crit Care"},{"key":"662_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0924-8579(00)00362-9","volume":"17","author":"KG Naber","year":"2001","unstructured":"Naber KG: Which fluoroquinolones are suitable for treatment of urinary tract infections?. International Journal of Antimicrobial Agents. 2001, 17: 331-341. 10.1016\/S0924-8579(00)00362-9.","journal-title":"International Journal of Antimicrobial Agents"},{"key":"662_CR4","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. [\n                    http:\/\/www.whocc.no\/atcddd\/\n                    \n                  ]"},{"issue":"11","key":"662_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.1368-5031.2005.00699.x","volume":"59","author":"C Fogarty","year":"2005","unstructured":"Fogarty C, Torres A, Choudri S, Haverstock D, Herrington J, Ambler J: Efficacy of Moxifloxacin for treatment of penicillin-, macrolide-, and multidrug resistant Streptococcus pneumonia in community-acquired pneumonia. J Clin Pract. 2005, 59 (11): 1253-1259. 10.1111\/j.1368-5031.2005.00699.x.","journal-title":"J Clin Pract"},{"key":"662_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2005.03.010","volume":"26","author":"S Simoens","year":"2005","unstructured":"Simoens S, Verhaegen J, Laekeman G, Peetermans WE: Treating respiratory tract infections in ambulatory care in Belgium: fluoroquiniolone consumption and resistance development. International Journal of Antimicrobial Agents. 2005, 26: 62-68. 10.1016\/j.ijantimicag.2005.03.010.","journal-title":"International Journal of Antimicrobial Agents"},{"key":"662_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijantimicag.2005.03.004","volume":"26","author":"L Saravolatz","year":"2005","unstructured":"Saravolatz L, Manzor O, Pawlak J, Belian B: Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptoccous pneumoniae. International Journal of Antimicrobial Agents. 2005, 26: 81-84. 10.1016\/j.ijantimicag.2005.03.004.","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"2","key":"662_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/01.sla.0000230024.84190.a8","volume":"244","author":"MA Malangoni","year":"2006","unstructured":"Malangoni MA, Song J, Herrington J, Choudrhri S, Pertel P: Randomized Controlled Trial of Moxifloxacin Compared With Piperacillin-Tazobactam and Amoxicillin-Clavulanate for the Treatment of Complicated Intra-abdominal Infections. Annals of Surgery. 2006, 244 (2): 204-11. 10.1097\/01.sla.0000230024.84190.a8.","journal-title":"Annals of Surgery"},{"issue":"2","key":"662_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/14656566.6.2.283","volume":"6","author":"M Miravitlles","year":"2005","unstructured":"Miravitlles M: Moxifloxacin in respiratory tract infections. Expert Opinion on Pharmacotherapy. 2005, 6 (2): 283-93. 10.1517\/14656566.6.2.283.","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"662_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ijantimicag.2004.01.013","volume":"24","author":"GE Stein","year":"2004","unstructured":"Stein GE, Schooley S: Urinary concentrations and bactericidal activities of newer fluoroquinolones in health volunteers. International Journal of Antimicrobial Agents. 2004, 24: 168-172. 10.1016\/j.ijantimicag.2004.01.013.","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"12","key":"662_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1371\/journal.pmed.0040329","volume":"4","author":"DA Rosen","year":"2007","unstructured":"Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ: Detection of Intracellular Bacterial Communities in Human Urinary Tract Infection. PLOS Medicine. 2007, 4 (12): 1949-58. 10.1371\/journal.pmed.0040329.","journal-title":"PLOS Medicine"},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/jac\/27.5.589","volume":"27","author":"DA Leigh","year":"1991","unstructured":"Leigh DA, Tait S, Walsh B: Antibacterial activity of Lomefloxacin. Journal of Antimicrobial Chemotherapy. 1991, 27: 589-98. 10.1093\/jac\/27.5.589.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 1","key":"662_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1086\/428052","volume":"41","author":"GA Jacoby","year":"2005","unstructured":"Jacoby GA: Mechanisms of Resistance to Quinolones. Clinical Infectious Diseases. 2005, 41 (Suppl 1): 120-6. 10.1086\/428052.","journal-title":"Clinical Infectious Diseases"},{"key":"662_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkl320","volume":"58","author":"H von Baum","year":"2006","unstructured":"von Baum H, Bommer M, Kern WV, MArre R, D\u00f6hner H, Kern P, Reuter S: Moxifloxacin prophylaxis in neutropenic patients. Journal of Antimicrobial Chemotherapy. 2006, 58: 891-4. 10.1093\/jac\/dkl320.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/00365549709019046","volume":"29","author":"JJ Joris","year":"1997","unstructured":"Joris JJ, Leur Van De PM, Vollar EJ, Janssen AHJM, Dofferhoff ASM: Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. Scandinavian Journal of Infections Disease. 1997, 29: 297-300.","journal-title":"Scandinavian Journal of Infections Disease"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-8-71\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-71","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T07:13:07Z","timestamp":1548141187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-8-71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,24]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-8-71","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,24]]},"article-number":"71"}}